Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design
- PMID: 35325621
- DOI: 10.1016/S2468-1253(22)00049-8
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design
Conflict of interest statement
I declare advisory boards for Gilead, Intercept, Pfizer, and NovoNordisk. Lecture fees from Dr Falk and Intercept. I am on a data safety monitoring board for Promethera.
Comment on
-
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Gastroenterol Hepatol. 2022 Jul;7(7):603-616. doi: 10.1016/S2468-1253(22)00017-6. Epub 2022 Mar 21. Lancet Gastroenterol Hepatol. 2022. PMID: 35325622 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical